Fenbendazole Oncology Guide

How does fenbendazole fight cancer?

Fenbendazole (FBZ) fights cancer through microtubule disruption, metabolic starvation, p53-mediated apoptosis, selective oxidative stress, and suppression of cancer stem cells. Although originally developed as a veterinary anthelmintic, extensive preclinical research and documented human case reports demonstrate that it engages several distinct anticancer mechanisms:

1. Microtubule Depolymerization & G2/M Cell Cycle Arrest

• Colchicine-Site Binding: FBZ binds to β-tubulin at the colchicine-binding site, acting as a moderate microtubule-destabilizing agent.

• Mitotic Disruption: By preventing tubulin polymerization, FBZ impairs mitotic spindle formation, leading to monopolar spindles and preventing proper chromosome segregation.

• G2/M Checkpoint Activation: This forces cancer cells into G2/M cell cycle arrest and mitotic catastrophe. Mechanistically, FBZ upregulates Cyclin B1, reduces inhibitory phosphorylation of CDK1 at Tyr15, downregulates Wee1 kinase, and activates cdc25C, locking the cell in a state that triggers programmed cell death.

2. Metabolic Starvation (Glucose Transport & Glycolysis Inhibition)

• Blocking Glucose Uptake: Cancer cells rely heavily on high rates of aerobic glycolysis (the Warburg effect). FBZ disrupts the microtubule-dependent membrane trafficking of glucose transporters, markedly suppressing GLUT1 and GLUT4 expression.

• Hexokinase II (HK II) Downregulation: FBZ inhibits Hexokinase II, the primary rate-limiting glycolytic enzyme that cancer cells use to generate ATP and prevent apoptosis. This dual blockade starves cancer cells of bioenergetic substrates and reduces tumor lactate production.

3. p53 Stabilization & Mitochondrial Apoptosis

• Proteasomal Inhibition: FBZ impairs the ubiquitin-proteasome system, preventing the rapid degradation of the p53 tumor suppressor protein and causing its intracellular accumulation.

• Mitochondrial Translocation: Monoubiquitinated p53 translocates to the mitochondria, inducing mitochondrial membrane depolarization, cytochrome c release, and activation of the caspase-3/7/9 and PARP apoptotic cascades.

• Downstream Target Induction: Activated p53 upregulates key target genes involved in cell cycle inhibition and metabolic regulation, including SCO2 and TIGAR.

4. Selective Oxidative Stress & Ferroptosis

• Selective ROS Accumulation: FBZ triggers the accumulation of intracellular reactive oxygen species (ROS) and superoxide in malignant cells (such as triple-negative breast cancer and lung cancer), while normal epithelial and non-transformed cells remain largely unaffected.

• Induction of Ferroptosis: In chemotherapy-resistant tumors (such as 5-FU-resistant colorectal cancer), FBZ induces p53-independent cell death pathways and ferroptosis (iron-dependent lipid peroxidation).

5. CSC Eradication & Anti-Metastatic Signaling

• Targeting Cancer Stem Cells (CSCs): FBZ depletes therapy-resistant stem-like subpopulations (such as cancer stem cells) in cervical and breast cancers. It downregulates core stemness self-renewal genes, including c-Myc, Oct4, Sox2, and Nanog.

• Inhibiting Metastasis: FBZ blocks the phosphorylation of NF-B p65 and suppresses matrix metalloproteinases (MMP-2 and MMP-9), inhibiting tumor cell migration, invasion, and epithelial-mesenchymal transition (EMT).

6. Human Clinical Observations & Safety Considerations

• Clinical Case Outcomes: Published case series (such as the 2021 Stanford University case report) have documented complete or near-complete radiographic responses in human patients with stage IV clear cell renal cell carcinoma, urothelial carcinoma, and diffuse large B-cell lymphoma who self-administered or concurrently received oral FBZ.

• Pharmacokinetic Limits: FBZ exhibits extremely low aqueous solubility, which restricts oral absorption and systemic bioavailability in humans.

• Hepatic Monitoring: Self-administration reports indicate that FBZ can occasionally cause drug-induced liver injury (hepatic dysfunction), which typically resolves rapidly upon discontinuing the medication.

  ---

  Title: The Antitumorigenic Potentials of Benzimidazole Anthelmintics as Repurposing Drugs

  Authors: Deok-Soo Son, Eun-Sook Lee, Samuel E. Adunyah

  Journal: Immune Network

  Publication Details: 2020, Vol. 20, No. 4, Article e29

  DOI: 10.4110/in.2020.20.e29

  Title: Teaching an old dog new tricks: The case of Fenbendazole

  Authors: Ioanna Vlachou, Panagiotis Parsonidis, Alexandra Mamagkaki, Ioannis Bouris, Ioannis Papasotiriou

  Journal: Cancer Treatment and Research Communications

  Publication Details: 2022, Vol. 32, Article 100601

  DOI: 10.1016/j.ctarc.2022.100601

  Title: Redox-mediated Anticancer Activity of Fenbendazole

  Authors: Severina Semkova, Boryana Nikolova, Dimitar Ivanov, Georgi Apostolov, Ivan Tsachev, Albena Alexandrova, Rumiana Bakalova, Zdravko Zlatev

  Journal: Anticancer Research

  Publication Details: 2023, Vol. 43, No. 3, pp. 1207–1212

  DOI: 10.21873/anticanres.16267

  Title: Fenbendazole inhibits cell proliferation and promotes apoptosis of ovarian cancer cells by inducing mitotic catastrophe

  Authors: Xin Wang, Wenda Tian, Na Wang, Xiaoxiao Yang, Lin Lin, Zhaocan Liu, Tian Tian, Chaoyan Wang, Hongying Yang, Yue Jia, Hongping Zhang

  Journal: BMC Cancer

  Publication Details: 2024, Vol. 24, Article 1593

  DOI: 10.1186/s12885-024-13361-9

  Title: Cocrystals of Fenbendazole with Enhanced in vitro Dissolution Performance

  Authors: K. Blessi Priyanka, T. S. Ramya, K. Swarnalatha, G. Sushmitha, A. Ara, T. S. Srujana, B. Swapna

  Journal: European Chemical Bulletin (Eur. Chem. Bull.)

  Publication Details: 2023, Vol. 12, Special Issue 8, pp. 9056–9061

  DOI: 10.31838/ecb/2023.12.Si8.826

  Title: Oral Fenbendazole for Cancer Therapy in Humans and Animals

  Authors: Jolie Nguyen, Thai Q. Nguyen, Bo Han, Ba X. Hoang

  Journal: Anticancer Research

  Publication Details: 2024, Vol. 44, No. 9, pp. 3725–3735

  DOI: 10.21873/anticanres.17197

  Title: Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Cell Cycle Arrest in A549 Lung Cancer Cells

  Authors: Thai Q. Nguyen, Jolie Nguyen, Bo Han, Ba X. Hoang

  Journal: Anticancer Research

  Publication Details: 2024, Vol. 44, No. 11, pp. 4761–4772

  DOI: 10.21873/anticanres.17302

  Title: Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-Immunotherapy Against Bladder Cancer

  Authors: Xiaojian Xu, Rui Liang, Anguo Zhao, Jun Zhang, Rongkang Li, Yang Liu, Dashi Deng, Qi Zhuang, Lisha Liu, Lei Peng, Miao Li, Xuedong Wei, Yuhua Huang, Shaohua Zhang, Liang Cheng, Jianquan Hou

  Journal: Advanced Science

  Publication Details: 2026, Vol. 13, No. 31, Article e2505669 / 74876

  DOI: 10.1002/advs.202505669

  Title: Case Studies of Patients Who Cured Their Own Stage 4 Cancers

  Author: Jacqueline

  Publication Platform: Deep Roots at Home

  Publication Date: August 14, 2024

  URL: deeprootsathome.com/case-studies-of-patients-who-cured-their-own-stage-4-cancers/

  Title: Exceptional Repositioning of Dog Dewormer: Fenbendazole Fever

  Authors: Tania Sultana, Umair Jan, Hyunsu Lee, Hyejin Lee, Jeong Ik Lee

  Journal: Current Issues in Molecular Biology (Curr. Issues Mol. Biol.)

  Publication Details: 2022, Vol. 44, No. 10, pp. 4977–4986

  DOI: 10.3390/cimb44100338

  Title: Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways

  Authors: Nidhi Dogra, Abhisheak Kumar, Tapas Mukhopadhyay

  Journal: Scientific Reports

  Publication Details: 2018, Vol. 8, Article 11926

  DOI: 10.1038/s41598-018-30158-6

  Title: Fenbendazole as a Treatment for Diffuse Large B-Cell Lymphoma

  Authors: Anas Abughanimeh, Theujus Evans, Alok Kallam

  Journal: Annals of Hematology & Oncology

  Publication Details: 2020, Vol. 7, No. 2, Article 1284

  Title: From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies

  Authors: Udayakumar Golla, Sagar Patel, Nirav Shah, Salvatore Talamo, Rahul Bhalodia, David Claxton, Sinisa Dovat, Arati Sharma

  Journal: Cancers

  Publication Details: 2024, Vol. 16, No. 20, Article 3454

  DOI: 10.3390/cancers16203454

  Title: Anticancer role of flubendazole: Effects and molecular mechanisms (Review)

  Authors: Xing Xing, Zongning Zhou, Hongwei Peng, Shaoping Cheng

  Journal: Oncology Letters

  Publication Details: 2024, Vol. 28, No. 6, Article 558

  DOI: 10.3892/ol.2024.14691

  Title: Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy

  Authors: Rosalba Florio, Simone Carradori, Serena Veschi, Davide Brocco, Teresa Di Genni, Roberto Cirilli, Adriano Casulli, Alessandro Cama, Laura De Lellis

  Journal: Pharmaceuticals

  Publication Details: 2021, Vol. 14, No. 4, Article 372

  DOI: 10.3390/ph14040372

  Title: Overcoming cancer therapeutic bottleneck by drug repurposing

  Authors: Ying Xia, Ming Sun, Hai Huang, Wei-Lin Jin

  Journal: Signal Transduction and Targeted Therapy

  Publication Details: 2024, Vol. 9, Article 101

  DOI: 10.1038/s41392-024-01808-1

  Title: Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics

  Authors: Bomi Song, Eun Young Park, Kwang Joon Kim, Sung Hwan Ki

  Journal: Cancers

  Publication Details: 2022, Vol. 14, No. 19, Article 4601

  DOI: 10.3390/cancers14194601

  Title: From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies

  Authors: Udayakumar Golla, Sagar Patel, Nirav Shah, Salvatore Talamo, Rahul Bhalodia, David Claxton, Sinisa Dovat, Arati Sharma

  Journal: Cancers

  Publication Details: 2024, Vol. 16, No. 20, Article 3454

  DOI: 10.3390/cancers16203454

  Title: Fenbendazole Enhancing Anti-Tumor Effect: A Case Series

  Authors: Ryan S. Chiang, Ali B. Syed, Jonathan L. Wright, Bruce Montgomery, Sandy Srinivas

  Journal: Clinical Oncology: Case Reports

  Publication Details: 2021, Vol. 4, No. 2, Article 1000159

  Title: Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers

  Authors: Chaoran Chen, Yueming Ding, Huiyang Liu, Mengyao Sun, Honggang Wang, Dongdong Wu

  Journal: International Journal of Molecular Sciences (Int. J. Mol. Sci.)

  Publication Details: 2022, Vol. 23, No. 1, Article 519

  DOI: 10.3390/ijms23010519

  Title: Unexpected Antitumorigenic Effect of Fenbendazole When Combined with Supplementary Vitamins

  Authors: Peng Gao, Chi V. Dang, John Watson

  Journal: Journal of the American Association for Laboratory Animal Science (J. Am. Assoc. Lab. Anim. Sci. / JAALAS)

  Publication Details: 2008, Vol. 47, No. 6, pp. 37–40

  Title: Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer Through Dual Targeting of Cancer Cells and Cancer Stem Cells: Evidence from In Vitro and In Vivo Models

  Authors: Xi Lei, Yi Wang, Yuanyuan Chen, Jinyue Duan, Xin Gao, Zhongyi Cong

  Journal: Molecules

  Publication Details: 2025, Vol. 30, No. 11, Article 2377

  DOI: 10.3390/molecules30112377

  Title: Evaluation of the Drug–Polymer Compatibility and Dissolution Behaviour of Fenbendazole–Soluplus® Solid Dispersions Prepared by Hot-Melt Extrusion

  Authors: Amirhossein Karimi, Gilberto S. N. Bezerra, Clement L. Higginbotham, John G. Lyons

  Journal: Polymers

  Publication Details: 2026, Vol. 18, No. 3, Article 333

  DOI: 10.3390/polym18030333

  Title: Drug repurposing from the perspective of pharmaceutical companies

  Authors: Y. Cha, T. Erez, I. J. Reynolds, D. Kumar, J. Ross, G. Koytiger, R. Kusko, B. Zeskind, S. Risso, E. Kagan, S. Papapetropoulos, I. Grossman, D. Laifenfeld

  Journal: British Journal of Pharmacology (Br. J. Pharmacol.)

  Publication Details: 2018, Vol. 175, No. 2, pp. 168–180

  DOI: 10.1111/bph.13858

  Title: Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy

  Authors: Rosalba Florio, Simone Carradori, Serena Veschi, Davide Brocco, Teresa Di Genni, Roberto Cirilli, Adriano Casulli, Alessandro Cama, Laura De Lellis

  Journal: Pharmaceuticals

  Publication Details: 2021, Vol. 14, No. 4, Article 372

  DOI: 10.3390/ph14040372

  Title: Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

  Authors: Peter Nygren, Mårten Fryknäs, Bengt Ågerup, Rolf Larsson

  Journal: Journal of Cancer Research and Clinical Oncology

  Publication Details: 2013, Vol. 139, No. 12, pp. 2133–2140

  DOI: 10.1007/s00432-013-1539-5

  Title: Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways

  Authors: Nidhi Dogra, Abhisheak Kumar, Tapas Mukhopadhyay

  Journal: Scientific Reports

  Publication Details: 2018, Vol. 8, Article 11926

  DOI: 10.1038/s41598-018-30158-6

  Title: Synergistic anti-tumor effect of fenbendazole and diisopropylamine dichloroacetate in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells

  Authors: Thai Q. Nguyen, Uyen T. T. Phan, Mao V. Can, Dang H. Nguyen, Bo Han, Ba X. Hoang

  Journal: Translational Lung Cancer Research (Transl. Lung Cancer Res.)

  Publication Details: 2025, Vol. 14, No. 7, pp. 2509–2521

  DOI: 10.21037/tlcr-2024-1272